Rozanolixizumab, brand name Rystiggo, was approved by the FDA last summer as a treatment for those with generalized Myasthenia gravis and anti-AChR or anti-MuSK antibodies. It is distributed with an under-the-skin infusion with an infusion pump once a week for six weeks, possibly more. https://myastheniagravisnews.com/news/fda-approves-rozanolixizumab-rystiggo-treat-gmg/
Have you started Rozanolixizumab/Rystiggo? Have you noticed any improvement or worsening of your symptoms? Any side effects?
Have you been talking to your doctor about starting this treatment in the future? What possible concerns do you have about it?
Log in to reply.